Kenneth C. Frazier
Merck & Co. CEO Kenneth C. Frazier

Stephanie Keith / Stringer / Getty Photography


Merck sparked a 132% surge in Pandion Therapeutics on Thursday after the pharmaceutical giant agreed to extinguish the biotech company for $1.85 billion.

Pandion is a scientific-stage biotechnology firm that is constructing therapeutics for sufferers residing with autoimmune ailments. Pandion’s lead candidate, PT101, carried out a Segment 1a trial earlier this year and is a doable medications for ulcerative colitis.

Merck will provoke a younger offer via a subsidiary to extinguish all prominent shares of Pandion for $60 per fragment. Shares of Pandion closed at $25.63 on Wednesday. The completion of the acquisition will require no longer no longer as a lot as a majority of Pandion shareholders tendering their shares to Merck. 

“Pandion has utilized its TALON know-how to form a sturdy pipeline of candidates designed to re-balance the immune response with likely capabilities across a huge array of autoimmune ailments,” said Dr. Dean Y. Li, president of Merck Learn Laboratories. 

The transaction is expected to halt within the first half of of 2021. 

Learn Extra

LEAVE A REPLY

Please enter your comment!
Please enter your name here